Výsledky vyhledávání

Akademický článek

PCV15, a pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in infants and children

Autor: Timothy J Chapman, Liset Olarte, Ghassan Dbaibo, Avril Melissa Houston, Gretchen Tamms, Robert Lupinacci, Kristen Feemster, Ulrike K Buchwald, Natalie Banniettis

Publikováno v: Expert Review of Vaccines, Vol 23, Iss 1, Pp 137-147 (2024)

Introduction Streptococcus pneumoniae is a causative agent of pneumonia and acute otitis media (AOM), as well as invasive diseases such as meningitis and bacteremia. PCV15 (V114) is a new 15-valent pneumococcal conjugate vaccine (PCV) approved for us

Externí odkaz: https://doaj.org/article/8a4c9057ccf6425a95168278db4e417f

Zobrazit plný text záznamu

Akademický článek

A phase 3, single-arm, open-label study to evaluate the safety, tolerability, and immunogenicity of a 15-valent pneumococcal conjugate vaccine, V114, in a 3+1 regimen in healthy infants in South Korea (PNEU-PED-KOR)

Autor: Alvino Maestri, Su Eun Park, Fiona Fernandes, Zhongyi “Lucy” Li, Yae-Jean Kim, Yun-Kyung Kim, Jin Lee, Ji Young Park, Dong Hyun Kim, GyongSeon Yang, Hyunjung Lim, Jin Oh Kim, Robert Lupinacci, Tina M. Sterling, Marissa Wilck, Alejandra Esteves-Jaramillo, Natalie Banniettis

Publikováno v: Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)

ABSTRACTThere is an ongoing burden of pneumococcal disease in children despite the use of pneumococcal conjugate vaccines (PCVs). This phase 3, open-label, single-arm, multisite, descriptive study was designed to evaluate the safety and immunogenicit

Externí odkaz: https://doaj.org/article/bee75b52b4b44c919cf78d85f82b27ea

Zobrazit plný text záznamu

Akademický článek

The Health and Economic Effects of PCV15 and PCV20 During the First Year of Life in the US

Autor: Aleksandar Ilic, Maria J. Tort, Alejandro Cane, Raymond A. Farkouh, Mark H. Rozenbaum

Publikováno v: Vaccines, Vol 12, Iss 11, p 1279 (2024)

(1) Background/Objectives: Two pneumococcal conjugate vaccines, 15-(PCV15) and 20-(PCV20) valent formulations, are routinely recommended for US children in a 3+1 schedule. The first three doses are administered during the first year of life at 2, 4,

Externí odkaz: https://doaj.org/article/80a73adcd0ab4c55b00f1901c00ebb59

Zobrazit plný text záznamu

Akademický článek

An indirect treatment comparison (ITC) and matching-adjusted indirect comparison (MAIC) between a 15-valent (V114) and a 20-valent (PCV20) pneumococcal conjugate vaccine among healthy infants

Autor: Shahrul Mt-Isa, Justin R. Chumbley, Emma L. Crawford, Natalie Banniettis, Ulrike K. Buchwald, Jessica Weaver, Thomas Weiss

Publikováno v: Expert Review of Vaccines, Vol 22, Iss 1, Pp 906-917 (2023)

Objectives Immunogenicity between 15-valent V114 (PCV15) and 20-valent PCV20 pneumococcal conjugate vaccines in healthy infants is compared in an indirect treatment comparison and matching-adjusted indirect comparison. Hypotheses: immunogenicity of V

Externí odkaz: https://doaj.org/article/fc924601a56e4328a69175c2ebf6d424

Zobrazit plný text záznamu

Akademický článek

Cost-Effectiveness Analysis of Routine Childhood Immunization with 20-Valent versus 15-Valent Pneumococcal Conjugate Vaccines in Germany

Autor: Min Huang, Jessica P. Weaver, Elamin Elbasha, Thomas Weiss, Natalie Banniettis, Kristen Feemster, Meghan White, Matthew S. Kelly

Publikováno v: Vaccines, Vol 12, Iss 9, p 1045 (2024)

This study aimed to evaluate the cost-effectiveness of routine childhood immunization with the 20-valent pneumococcal conjugate vaccine (PCV20) in a four-dose regimen (3 + 1 schedule) versus the 15-valent PCV (PCV15/V114) in a three-dose regimen (2 +

Externí odkaz: https://doaj.org/article/de7674a488e3451ebfcd4fe0e832ec3b

Zobrazit plný text záznamu

Akademický článek

Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece

Autor: George Gourzoulidis, Myrto Barmpouni, Vasiliki Kossyvaki, Jeffrey Vietri, Charalampos Tzanetakos

Publikováno v: Frontiers in Public Health, Vol 11 (2023)

ObjectiveHigher valency pneumococcal conjugate vaccines (PCVs) are expected to improve protection against pneumococcal disease through coverage of additional serotypes. The aim of the present study was to evaluate the cost-effectiveness of 20-valent

Externí odkaz: https://doaj.org/article/9eeacb46524d4f8dada9aed11373b463

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Safety and immunogenicity of a 15-valent pneumococcal conjugate vaccine in Japanese healthy infants: A Phase I study (V114-028)

Autor: Yasunori Ishihara, Haruo Kuroki, Hidenobu Hidaka, Kazuyuki Iwai, Keiko Wan, Masayoshi Shirakawa, Miyuki Sawata

Publikováno v: Human Vaccines & Immunotherapeutics, Vol 19, Iss 1 (2023)

This Phase I study evaluated the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine (PCV), via subcutaneous (SC) or intramuscular (IM) administration, in healthy Japanese infants 3 months of age. A total of 1

Externí odkaz: https://doaj.org/article/bd2f6571c8134d74b33d486dc8c24bf6

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání